New combo therapy for prostate cancer shows promise in early trial

NCT ID NCT01517451

Completed Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1/2 trial tested a combination of stereotactic body radiation therapy (5 high-dose sessions) and 4 months of hormone therapy in 45 men with intermediate-risk prostate cancer. The goal was to see how well this approach controls cancer and what side effects occur. Results help guide future treatment options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy and hormone therapy (androgen deprivation therapy)
What this could lead to: If successful, this combination could offer a shorter, more convenient treatment option that controls prostate cancer for years with manageable side effects.
What could go wrong: This is an early-phase trial with only 45 participants, so results may not apply to all patients. There is a risk of urinary or bowel side effects from the radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA OF THE PROSTATE

Contacts and locations

Show contact details

Locations

Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
Suburban Hospital

Bethesda, Maryland, 20814, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.